CSTL Q2 2019 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$772M

Q2 2019 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$11M+169.9% YoY

Gross Profit

$9M81.4% margin

Operating Income

$607,6215.7% margin

Net Income

-$1M-11.8% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+23.2%

Cash Flow

Operating Cash Flow

$481,736

Free Cash Flow

$300,886

Stock-Based Comp.

$138,808

Balance Sheet

Total Assets

$33M

Total Liabilities

$37M

Stockholders' Equity

-$4M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$4M	+169.9%
Gross Profit	$9M	$3M	+229.7%
Operating Income	$607,621	-$3M	+122.8%
Net Income	-$1M	-$3M	+59.8%